好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Age Related Recovery from Acute Optic Neuritis in Multiple Sclerosis
MS and Related Diseases
P04 - (-)
120
BACKGROUND: AON attacks are common in both POMS and AOMS patients, but the severity and level of recovery from these attacks are variable across patients. Identification of predictors associated with attack severity and recovery may aid in clinical care.
DESIGN/METHODS: Both the AOMS (n=68) and POMS patients (n=24) were identified from CLIMB study at Partners Adult and Pediatric MS Centers, who presented with AON as their initial symptom after the year 2000. For each attack, a chart review was completed to assess initial severity of attack and level of recovery from attack. Severity was classified based on visual acuity at the visit closest to the attack. Attacks were classified as mild (20/40), moderate (20/50-20/190) and severe (>20/200). Recovery from AON was classified based on the change in visual acuity at clinic visit, 1 year after onset. Recovery was classified as complete (20/20 or pre-attack acuity), fair (20/40) and poor (>20/50 or worse). The proportion of patients with each level of severity and recovery for initial AON attack was compared in two groups using Fisher's exact test. The probability of complete recovery including all attacks was assessed using generalized estimating equations.
RESULTS: The proportion of AOMS patients with mild/moderate/severe AON attack at first symptom (13.4% /32.4%/54.4%) was not significantly different than in POMS (8.3%/25%/66.7%, p=0.66). Conversely, proportion of POMS patients who experienced complete recovery from the initial AON attack was significantly higher than in AOMS (91% vs.70%, p=0.05). When all AON attacks were considered (including first episode), POMS patients were more likely to experience complete recovery (p=0.03).
CONCLUSIONS: Compared to AOMS, POMS patients are more likely to experience complete recovery from AON attacks.
Authors/Disclosures
Muhammad Taimur A. Malik, MD (St Lukes)
PRESENTER 		Dr. Malik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Genetech . Dr. Malik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jansen . Dr. Malik has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for EMD serono. The institution of Dr. Malik has received research support from National MS Society .
Brian C. Healy The institution of Mr. Healy has received research support from Analysis Group. The institution of Mr. Healy has received research support from Bristol-Myers Squibb. The institution of Mr. Healy has received research support from Verily Life Sciences. The institution of Mr. Healy has received research support from Novartis. The institution of Mr. Healy has received research support from Merck Serono. The institution of Mr. Healy has received research support from Genzyme.
Leslie A. Benson, MD (Children's Hospital Boston) The institution of Dr. Benson has received research support from ROHHAD Fight, Inc. The institution of Dr. Benson has received research support from NIH. The institution of Dr. Benson has received research support from Roche/Genentech. Dr. Benson has received personal compensation in the range of $0-$499 for serving as a consultant with MA Department of public health. Dr. Benson has received personal compensation in the range of $10,000-$49,999 for serving as a consultant with National vaccine injury compensation program.
Said R. Beydoun, MD, FAAN (University of Southern California Healthcare Consultation Center 2) Dr. Beydoun has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Alexion. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Janssen. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CSL. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Beydoun has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Pfizer. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Takeda. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alnylam. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for CSL. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Takeda. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AstraZeneca. Dr. Beydoun has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Beydoun has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Janssen. The institution of Dr. Beydoun has received research support from Abcuro. The institution of Dr. Beydoun has received research support from Sean Healy & AMG Center for ALS. The institution of Dr. Beydoun has received research support from Regeneron. The institution of Dr. Beydoun has received research support from RemeGen. The institution of Dr. Beydoun has received research support from Sanofi. The institution of Dr. Beydoun has received research support from Novartis.
Tanuja Chitnis, MD, FAAN (Brigham and Women's Hospital) Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Chitnis has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche-Genentech. Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Octave Biosciences. Dr. Chitnis has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Chitnis has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. The institution of Dr. Chitnis has received research support from Novartis. The institution of Dr. Chitnis has received research support from Sanofi. The institution of Dr. Chitnis has received research support from Octave. The institution of Dr. Chitnis has received research support from Genentech-Roche. The institution of Dr. Chitnis has received research support from Tiziana Life Sciences. The institution of Dr. Chitnis has received research support from Bristol-Myers Squibb. The institution of Dr. Chitnis has received research support from Wesley Clover.